Bergenbio ASA (ONCIN.OL)
Oslo Børs · Financial statements, TTM figures and earnings dates
In fiscal year 2024 (ended December 31, 2024), Bergenbio ASA reported revenue of NOK 848.0K and net income of −NOK 139.3M. Annual financial statements are available for fiscal years 2020 to 2024, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| NOK | FY2024 2024-12-31 | FY2023 2023-12-31 | FY2022 2022-12-31 | FY2021 2021-12-31 | FY2020 2020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | NOK 848.0K | NOK 354.0K | NOK 389.0K | NOK 774.0K | NOK 601.0K |
| Operating income | −NOK 151.2M | −NOK 191.8M | −NOK 305.6M | −NOK 314.5M | −NOK 261.1M |
| Net income | −NOK 139.3M | −NOK 190.4M | −NOK 302.1M | −NOK 309.4M | −NOK 257.0M |
| Diluted EPS | −NOK 3.95 | −NOK 0.13 | −NOK 3.41 | −NOK 3.52 | −NOK 3.43 |
| Cash flow | |||||
| Operating cash flow | −NOK 153.2M | −NOK 225.1M | −NOK 288.2M | −NOK 303.3M | −NOK 234.3M |
| Capital expenditure | – | – | – | – | NOK 67.0K |
| Free cash flow | – | – | – | – | −NOK 234.4M |
| Balance sheet | |||||
| Cash and equivalents | NOK 140.2M | NOK 156.4M | NOK 150.8M | NOK 436.6M | NOK 721.6M |
| Total assets | NOK 155.8M | NOK 174.3M | NOK 166.7M | NOK 450.2M | NOK 738.2M |
| Total liabilities | NOK 33.1M | NOK 46.9M | NOK 78.2M | NOK 65.8M | NOK 68.0M |
| Total debt | – | – | – | NOK 942.0K | NOK 1.4M |
| Shareholders' equity | NOK 122.7M | NOK 127.5M | NOK 88.5M | NOK 384.4M | NOK 670.2M |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in NOK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full ONCIN.OL page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open ONCIN.OL financials →